Progress of minimal residual disease surveillance in B-cell lymphoma
10.3760/cma.j.cn115356-20220727-00220
- VernacularTitle:微小残留病监测在B细胞淋巴瘤中的研究进展
- Author:
Yanshan HUANG
1
;
Lugui QIU
;
Shuhua YI
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Lymphoma, B-cell;
Minimal residual disease;
Hematological disease;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2023;32(6):373-377
- CountryChina
- Language:Chinese
-
Abstract:
B-cell lymphoma is a group of heterogeneous hematologic malignant tumors originating from B cells, and it could be divided into invasive B-cell lymphoma and inert B-cell lymphoma. Currently, although disease remission rate has reached a high level, some patients still develop disease relapse or progression, thus, it is important to regularly monitor the disease and early identify the recurrence. At present, the recurrence of lymphoma mainly depends on imaging and clinical evaluation. However, some studies have shown that the minimal residual disease (MRD) monitoring based on flow or second-generation sequencing can provide a more accurate assessment of the depth of remission, predict the disease prognosis, and identify the early disease recurrence. This review summarizes the application of MRD in indolent lymphoma and aggressive lymphoma, mainly including the detection methods of MRD, research status and the application prospect of MRD in different lymphomas.
